Elsevier

Urology

Volume 27, Issue 3, March 1986, Pages 221-228
Urology

Scientific article
Objective response and disease outcome in 59 patients with stage D2 prostatic cancer treated with either buserelin or orchiectomy Disease aggressivity and its association with response and outcome

https://doi.org/10.1016/0090-4295(86)90278-5Get rights and content

Abstract

A comparative study was done in 59 recently diagnosed Stage D2 prostatic cancer patients treated with either long-term GnRH-A (Buserelin) (N = 42) or with orchiectomy (N = 17) and followed up for three years. The suppressed limits of plasma testosterone and estradiol levels after eight-week follow-up as well as the objective clinical response and disease outcome were found to be similar with either treatment. Hot flushes and loss of libido were noticed in both groups throughout the follow-up period; however, there were no other side effects. Analysis of Stage D2 patients based on their time of death enables us to identify non-hormonal variables which, in the form of an aggressiveness score, correlated well with both clinical response and disease outcome. These data confirm that (1) Buserelin is an effective and safe alternative to orchiectomy in advanced prostatic cancer, and (2) in clinical studies a multifactor aggressiveness score is useful for analyzing clinical efficacy data. Prospective application of that score may enable predictability of patient response and influence patient management.

References (26)

  • V. Borgman

    Sustained suppression of testosterone production by the luteinizing-hormone, releasing hormone agonist Buserelin in patients with advanced prostate carcinoma: a new therapeutic approach

    Lancet

    (1982)
  • R.J. Santen

    Long-term effects of administration of a gonadotropin-releasing hormone superagonistic analog in men with prostatic cancer

    J Clin Endocrinol Metab

    (1984)
  • G. Tolis

    Advanced prostatic adenocarcinoma: biological aspects and effects of androgen deprivation achieved by castration or agonistic analogues of LHRH

    Med Onc Tumour Pharmacother

    (1984)
  • Cited by (45)

    • Mechanisms of bone metastasis in prostate cancer: clinical implications

      2008, Best Practice and Research: Clinical Endocrinology and Metabolism
      Citation Excerpt :

      Patients that initially present with localized cancer (confined to the prostate gland) can be treated by potentially curative therapies such as radical prostatectomy or radiation therapy (either external-beam radiotherapy or sealed-source radiotherapy, also known as brachytherapy). Although the majority of patients present with clinically localized disease, a sizeable proportion of these patients will ultimately relapse, with the reported 5-year failure rate ranging from 17% to 34%.11,54–57 This indicates the residual postoperative presence of locally invasive, circulating and/or distant micrometastatic cancer cells.58

    • Skeletal metastases in advanced prostate cancer: cell biology and therapy

      1995, Critical Reviews in Oncology and Hematology
    • Luteinising Hormone Releasing Hormone

      1993, Pharmacochemistry Library
    View all citing articles on Scopus
    View full text